Summary: AB&B BIO-TECH-B (02627) reported Revenue of 259.61M（+397.65%）; Operating profit of -241.00M（+42.36%）; Net profit attributable to owners of -258.72M（+39.09%）.
ReportedYoY
Prior YearYoY
RevenueUp YoY
259.61M397.65%
52.17M--
Operating profitUp YoY
-241.00M42.36%
-418.13M--
Net profit attributable to ownersUp YoY
-258.72M39.09%
-424.74M--
Revenue
Reported
Operating profit
Reported
Net profit attributable to owners
Reported
Gross marginYoY
FY 2023
FY 2024
Profitability
(YoY)
Growth
(YoY)
Asset Quality
(YoY)
Cash Generation
(YoY)
RevenueYoY
FY 2023
FY 2024
Revenue
(YoY)
Cost
(YoY)
Expenses
(YoY)
Interest
(YoY)
Profit
(YoY)
Cash and cash equivalentsYoY
FY 2023
FY 2024
Assets
(YoY)
Liabilities
(YoY)
Equity
(YoY)
Net cash from operating activitiesYoY
FY 2023
FY 2024
Operating Cash Flow
(YoY)
Investing Cash Flow
(YoY)
Financing Cash Flow
(YoY)
Net Change in Cash
(YoY)
Financial data: HKEXnews annual and interim reports; pre-listing years from the prospectus. YoY for ratios is the change in percentage points; ROE and ROA use annual reports only.
About this page
This page shows AB&B BIO-TECH-B (02627) historical financial statements and corporate actions. Financial data comes from public financial disclosures in HKEX display documents, grouped by reporting period; corporate actions come from HKEXnews announcements.
